Today The Zimmer Biomet Holdings, Inc. (ZBH) PT Raised to $151.00

Today The Zimmer Biomet Holdings, Inc. (ZBH) PT Raised to $151.00

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) had its target price hoisted by Needham & Company LLC to $151.00 in a research note issued to investors on Wednesday. Needham & Company LLC’s price objective points to a potential upside of 31.81% from the company’s current price.

Several other equities analysts have also commented on ZBH. RBC Capital Markets restated an “outperform” rating and set a $130.00 price target (down previously from $143.00) on shares of Zimmer Biomet Holdings in a research report on Tuesday, November 1st. J P Morgan Chase & Co set a $134.00 price target on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a research report on Thursday, January 5th. Canaccord Genuity restated a “buy” rating and set a $130.00 price target (down previously from $150.00) on shares of Zimmer Biomet Holdings in a research report on Monday, October 31st. Northcoast Research lowered shares of Zimmer Biomet Holdings from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 8th. Finally, Jefferies Group LLC lowered their price target on shares of Zimmer Biomet Holdings from $150.00 to $129.00 and set a “buy” rating for the company in a research report on Tuesday, November 1st. Four investment analysts have rated the stock with a hold rating and twenty have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $130.60.

Zimmer Biomet Holdings (NYSE:ZBH) traded up 0.57% during midday trading on Wednesday, reaching $115.21. 362,153 shares of the company’s stock were exchanged. The firm has a market capitalization of $23.08 billion, a P/E ratio of 64.51 and a beta of 1.23. The stock’s 50 day moving average is $107.15 and its 200 day moving average is $117.96. Zimmer Biomet Holdings has a 52 week low of $88.27 and a 52 week high of $133.21.

Zimmer Biomet Holdings (NYSE:ZBH) last released its earnings results on Monday, October 31st. The company reported $1.79 earnings per share for the quarter, meeting the consensus estimate of $1.79. Zimmer Biomet Holdings had a net margin of 3.46% and a return on equity of 16.48%. The firm earned $1.83 billion during the quarter, compared to analyst estimates of $950.20 million. During the same quarter in the previous year, the firm earned $1.64 earnings per share. The firm’s revenue for the quarter was up 4.0% compared to the same quarter last year. On average, analysts expect that Zimmer Biomet Holdings will post $7.92 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 27th. Stockholders of record on Friday, December 30th will be issued a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.84%. The ex-dividend date of this dividend is Wednesday, December 28th. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 75.00%.

In related news, insider David A. Jr. Nolan sold 5,050 shares of the company’s stock in a transaction on Friday, December 2nd. The stock was sold at an average price of $101.11, for a total transaction of $510,605.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.22% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Parkside Financial Bank & Trust boosted its stake in shares of Zimmer Biomet Holdings by 0.5% in the third quarter. Parkside Financial Bank & Trust now owns 964 shares of the company’s stock valued at $125,000 after buying an additional 5 shares during the last quarter. IFP Advisors Inc boosted its stake in shares of Zimmer Biomet Holdings by 0.5% in the second quarter. IFP Advisors Inc now owns 1,507 shares of the company’s stock valued at $181,000 after buying an additional 8 shares during the last quarter. Cypress Wealth Advisors LLC boosted its stake in shares of Zimmer Biomet Holdings by 0.4% in the second quarter. Cypress Wealth Advisors LLC now owns 3,081 shares of the company’s stock valued at $371,000 after buying an additional 11 shares during the last quarter. Advisory Services Network LLC boosted its stake in shares of Zimmer Biomet Holdings by 0.6% in the second quarter. Advisory Services Network LLC now owns 2,496 shares of the company’s stock valued at $301,000 after buying an additional 15 shares during the last quarter. Finally, Capital One National Association boosted its stake in shares of Zimmer Biomet Holdings by 0.3% in the third quarter. Capital One National Association now owns 5,670 shares of the company’s stock valued at $738,000 after buying an additional 15 shares during the last quarter. Institutional investors and hedge funds own 85.86% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Related posts

Leave a Comment